Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cambodia antimalarial efficacy study of dihydroartemisinin-piperaquine, artesunate-mefloquine, and chloroquine
ACTRN12612000183886Phase 4Completed
- Sponsor
- Institut Pasteur du Cambodge
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dihydroartemisinin + piperaquine, artesunate + mefloquine and chloroquine in Malaria and malaria (4 arms), sponsored by Institut Pasteur du Cambodge. Primary endpoints: Adequate clinical and parasitological response and PCR-corrected ACPR. Started Sep 2009; status: completed.
02
Drugs
dihydroartemisinin + piperaquineartesunate + mefloquinechloroquine
03
Conditions
Malariamalaria
Beyond the preview
Go deeper on ACTRN12612000183886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000183886.